Venom conjugated polylactide applied as biocompatible material for passive and active immunotherapy against scorpion envenomation

Highlights • Anionic biodegradable nanoparticles are coated by venom fraction: AahG50, BotG50. • We demonstrate innocuity of BotG50-coated PLA after injections to mice. • We demonstrate effective toxicity decrease of AahG50-coated PLA in mice. • Immune sera neutralized LD50 doses of AahG50 and BotG5...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2016-04, Vol.34 (15), p.1810-1815
Hauptverfasser:	Ayari-Riabi, Sana, Trimaille, Thomas, Mabrouk, Kamel, Bertin, Denis, Gigmes, Didier, Benlasfar, Zakaria, Zaghmi, Ahlem, Bouhaouala-Zahar, Balkiss, Elayeb, Mohamed
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Immunologic - chemistry Adsorption Allergy and Immunology Androctonus australis Animals Antigens Antitoxins Antivenins - chemistry Antivenins - therapeutic use Biochemistry, Molecular Biology Biocompatible Materials - chemistry Biodegradation Buthus occitanus tunetanus Comparative studies Detoxification Female Immune response Immune system Immunization Immunogenicity Immunology Immunoprotection Immunotherapy Immunotherapy, Active Life Sciences Mice Molecular weight Nanoparticles - chemistry Neutralization Neutralization Tests PLA nanoparticles Polyesters - chemistry Polymers Public health Scorpion Venoms - immunology Scorpions Toxic venom fraction Toxicity Tests Toxins Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Anionic biodegradable nanoparticles are coated by venom fraction: AahG50, BotG50. • We demonstrate innocuity of BotG50-coated PLA after injections to mice. • We demonstrate effective toxicity decrease of AahG50-coated PLA in mice. • Immune sera neutralized LD50 doses of AahG50 and BotG50 by a factor of 12.75 and 14. • Mice are fully protected against 1.8 × LD50 of AahG50 dose given at the 6th month.
ISSN:	0264-410X 1873-2518 0264-410X
DOI:	10.1016/j.vaccine.2016.02.030